Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 4/20 | 0.38 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 8/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16065653 | 0.91 | AURKA (0.44) | RETAURKAAURKBEGFR | |
| SCHEMBL17452597 | 0.88 | PAK1 (0.39) | RETAURKAAURKBEGFR | |
| SCHEMBL16065656 | 0.88 | AURKA (0.37) | RETAURKAAURKBEGFR | |
| SCHEMBL17175431 | 0.87 | KDR (0.41) | BRAFIGF1RRETAURKAAURKB | |
| SCHEMBL17175487 | 0.87 | IGF1R (0.38) | IGF1RAURKAAURKBEGFR | |
| SCHEMBL17452569 | 0.87 | AURKA (0.36) | RETAURKAAURKBEGFR | |
| SCHEMBL15704921 | 0.87 | IGF1R (0.44) | IGF1RRETAURKAAURKB | |
| SCHEMBL15704975 | 0.87 | AURKA (0.42) | RETAURKAAURKB | |
| SCHEMBL17175699 | 0.86 | EGFR (0.49) | RETAURKAAURKBEGFR | |
| SCHEMBL17175489 | 0.85 | IGF1R (0.41) | IGF1RRETAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9458137-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | BRAF 336/4885IGF1R 296/4885RET 965/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | BRAF 324/4885IGF1R 217/4885RET 991/4885 |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | GRK5, GRK3, CDK5 | BRAF 336/4885IGF1R 296/4885RET 965/4885 |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | BRAF 324/4885IGF1R 217/4885RET 991/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | BRAF 336/4885IGF1R 296/4885RET 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.